Management team of C3T

He defended his PhD in 2008, studying fundamental aspects of cytotoxic lymphocyte recognition and killing of target cells at the National Institutes of Health (NIH), MD, USA. 

He has been a group leader at KI since 2011, publishing highly-cited papers on human NK cell and CD8⁺ T cell differentiation and effector function. Bryceson co-chairs the Center for on Hematology and Regenerative Medicine (HERM) within the Department of Medicine Huddinge. The overarching goal of HERM is to bring to together basic and clinical competences to pursue cutting-edge research, ultimately translating novel scientific findings into the clinic and thereby improve patient outcomes. 

Bryceson also has a 30% clinical obligation with the Division of Clinical Immunology and Transfusion Medicine at Karolinska University Hospital, where he contributes to diagnosis and understanding of life-threatening primary immunodeficiencies affecting lymphocyte cytotoxicity.

She defended her PhD in 2011 from the Netherlands Cancer Institute, where she pionereed lineage tracing technology for fate mapping of individual naïve T cells. She conceptualized that while individual T cell clones produce functionally diverse progeny, robustness of T cell responses is provided by averaging highly divergent behaviors of individual T cell clones. 

Supported by the prestigious, international Cancer Research Institute Irvington postdoctoral fellowship, she studied the migratory and functional heterogeneity within CD8⁺ T cell populations at Harvard University, USA. 

In 2017, she was recruited as an independent investigator to the Department of Medicine Solna, KI, where her research is focused on CD8⁺ T cell differentiation in infection and cancer, largely using mouse models. Together with Isabelle Magalhaes she organizes a seminar series with outstanding international speakers for KI immunologists.

She defended her PhD in 2009 from KI, studying how vaccines can induce strong CD8⁺ T cell-mediated immunity to intracellular pathogens. 

After postdoctoral studies in France studying MAIT cells, she joined the Department of Oncology and Pathology, KI in 2015, where her research has since been focused on developing CAR T cell protocols for treatment of ovarian cancer, in part using xenogenic animal models. 

She collaborates with pioneers in the CAR T cell field such as Steve Rosenberg (NIH) and Michel Sadelain (Memorial Sloan Kettering). She has extensive teaching experience and together with Gerlach organizes a seminar series with outstanding international speakers for KI immunologists.

He defended his PhD in 2006 from KI, studying the TCR/MHC class I interaction in viral diseases. 

Following postdoctoral studies, he established a research group focused on immune therapy using cells and multi-specific antibodies directed against viruses as well as the protective roll of non-conventional T cells in cancer. In parallel, he has had several leadership positions within the Karolinska University Hospital, including directing research at the Centre for Allogeneic Stem Cell Transplantation (CAST). 

His clinical obligations include oversight of good manufacturing procedure (GMP) cell production for adoptive therapies. At the Department of Clinical Science, Intervention and Technology, KI, he leads the Division of Therapeutic Immunology and Transfusion Medicine (TITM).

He received his medical and doctoral degree in 1999 from the University of Göttingen. Trained in Internal Medicine, Hematology and Oncology at the University of Freiburg he was awarded a clinical postdoctoral fellowship at the NIH where he initaited clinical trials as a PI, he has since devoted his career to the development of advanced therapy medicinal products (ATMP) in cancer care.

Mielke is one of Europe's pioneers in CAR T-cell therapy, being one of the first in Germany treating patients with CAR T-cells in 2016 as part of the JULIET trial. He was recruited to KI/K in 2017 as full professor of hematology and cellular therapy at Department of Laboratory Medicine and the Department of Medicine Huddinge to head the Department for Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST) and act as scientfic director for the cancer center. Today, CAST performs around 120-130 treatments a year in both children and adults.

He was the first to perform standard of care CAR T cell therapy in Sweden, has recruited several international trials to Karolinska and taken a leading role in the foundation of Karolinska Comprehensive Cancer Center and Karolinska ATMP Center. He founded SWECARNET, Sweden’s CAR T cell network, a co-creational cooperation between academia, healthcare and industry to foster access to CAR T cell therapy for all patients in Sweden.